Yazar "Ozdemir, N." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Bioequivalence study of two long-acting oxytetracycline formulations in sheep(Springer, 2006) Ozdemir, N.; Yildirim, M.Two commercially available long-acting oxytetracycline hydrochloride formulations (Primamycin LA (Pfizer) and Terrallent 20% LA (I.E. Ulagay)) were administered by the intramuscular route to 20 clinically healthy sheep at a dose of 20 mg/kg. The study was performed in a two-period crossover design. Plasma samples were analysed by high-pressure liquid chromatography. The mean maximum concentrations (C-max) was 8.00 +/- 2.05 mu g/ml and 8.61 +/- 1.42 mu g/ml, respectively. The mean area under the concentration time curve (AUC) values were 154.95 +/- 50.37 (mu g h)/ml and 161.70 +/- 47.02 (mu g h)/ml, respectively. The 90% confidence intervals for the ratio of C-max and AUC values for the test and reference product are within the interval 70-143% for C-max and interval 80-125% for AUC proposed by EMEA. It was concluded that Primamycin LA and Terralent 20% LA formulations are bioequivalent in their rate and extent of drug absorbtion.Öğe Childhood, adolescents, and young adults (age 25 and younger) colorectal cancer: A multicenter study(Amer Soc Clinical Oncology, 2011) Kaplan, M. A.; Isikdogan, A.; Gumus, M.; Arslan, U. Yalcintas; Geredeli, C.; Ozdemir, N.; Koca, D.[Abstract Not Available]Öğe The impact of bevacizumab usage on patients who were curative resected for liver-confined metastases from colorectal cancer(Amer Soc Clinical Oncology, 2011) Turan, N.; Koca, D.; Dane, F.; Ozdemir, N.; Ustaalioglu, B. B. Oven; Oztop, I.; Ulas, A.[Abstract Not Available]Öğe Is lymph node ratio (LNR) having additional contribution for predict prognosis on pathologic lymph node staging in node -positive breast cancer patients?(Amer Assoc Cancer Research, 2016) Kaplan, M. A.; Odabasi, H.; Ozdemir, N.; Harputluoglu, H.; Aliustaoglu, M.; Berk, V.; Gunaydin, Y.[Abstract Not Available]Öğe Outcome of operable male breast carcinoma: One hundred eighteen patients(Amer Soc Clinical Oncology, 2011) Arslan, U. Yalcintas; Oksuzoglu, O. B.; Ozdemir, N.; Aksoy, S.; Alkis, N.; Durnali, A. Gok; Kaplan, M. A.[Abstract Not Available]Öğe PROGNOSTIC FACTORS AND TREATMENT OUTCOMES OF PATIENTS WITH UTERINE LEIOMYOSARCOMA: A RETROSPECTIVE STUDY OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY(Oxford Univ Press, 2012) Durnali, A.; Tokluoglu, S.; Ozdemir, N.; Inanc, M.; Alkis, N.; Zengin, N.; Sonmez, O. U.[Abstract Not Available]
